TSA Exit Acceleration
A healthcare exit needs care protected first.
Fixed-fee scope to sequence the exit around payer enrollment, HIPAA, and continuity of care. Senior team on day one. The first conversation is always free.
A Healthcare TSA exit is governed less by technology than by the duty not to disrupt care. Patient data, HIPAA obligations, clinical systems, and payer enrollment dictate what can move, when, and to whom. Every move in it ties back to the broader TSA exit strategy a disciplined buyer runs.
In most carve-outs the long pole is systems. In healthcare it is the payer relationship. A Newco that delivers or supports care needs to be enrolled and credentialed with commercial and government payers under its own identifiers before it can bill for anything it does after the transition. During the TSA the seller's entity and provider numbers often carry the billing. None of that transfers by flipping a switch.
Enrollment is the gating item. Payer enrollment and provider credentialing run on the payer's and the government's clock, measured in months, and a gap means care delivered that cannot be billed under a valid contract. Revenue stops even though the operation runs. The Newco has to hold its own enrollments and contracts before the seller stops billing on its behalf.
The buyer-side discipline is to start enrollment and credentialing the day the deal signs, not when the TSA exit approaches. These timelines depend on counterparties the buyer does not control, and they cannot be accelerated by spending. Every other workstream can be executed cleanly and the exit still strands revenue if the Newco cannot bill. Sequence the rest behind this.
The TSA often has to cover revenue cycle and billing services longer than a commercial carve-out would tolerate, because the seller's payer relationships and claims infrastructure cannot be replicated quickly. That extended dependency makes the commercial terms of those services unusually important. The buyer negotiates them knowing it cannot rush a payer.
Protected health information turns ordinary separation tasks into regulated events. Patient data cannot transfer to a system or a party without the right agreements and safeguards in place. A routine migration that would be a weekend task elsewhere becomes a controlled transfer governed by business associate agreements, access controls, and the breach exposure that follows any mistake.
The buyer maps the data landscape before any record moves. Which systems hold protected health information, which vendors are business associates, and which agreements have to be in place between seller, Newco, and every third-party that touches the data. That map governs how the migration is designed and which transfers can happen on the normal track.
Access is the trap. During a TSA the seller's administrators often retain access to systems holding patient data. Every retained access point is a HIPAA exposure that has to be justified, logged, and closed at exit. The buyer audits seller side access to systems containing protected health information and closes any gap before it becomes a reportable breach rather than a managed risk.
The exit is not complete when the data has moved. It is complete when the Newco can demonstrate a privacy and security program of its own: a risk assessment, trained workforce, and the safeguards the regime requires. The seller provided that umbrella during the TSA. Standing up the Newco's own compliance program is a named workstream, not an assumption.
Clinical systems support live patient care, and they do not absorb disruption gracefully. Electronic health records, scheduling, pharmacy, and laboratory systems all touch care delivery. A TSA exit that interrupts a clinical system during operating hours is not a cost problem. It is a patient safety problem with regulators and clinicians who have a long memory. Continuity of care is the constraint the entire exit is designed around.
The buyer maps every clinical workflow against the systems and services the TSA covers. The exit sequence has to ensure that no clinician loses access to the record, the order set, or the medication system they depend on during a care critical window. That often means timing cutover around low volume periods and validating in a live clinical context before the seller's version is switched off.
Record integrity deserves specific attention. Migrating an electronic health record without preserving the full clinical history, allergies, medications, and results can put care at risk in ways that do not show up until a clinician needs the missing data. The migration is validated against record completeness and clinical usability, not just whether the system loads.
Interfaces are the hidden dependency. Healthcare runs on connections between systems: lab feeds, pharmacy interfaces, and health information exchange connections. Each interface that the seller maintained has to be rebuilt and tested for the Newco. A migration that moves the core system but loses the interfaces leaves clinicians with a record that no longer talks to the lab or the pharmacy.
Healthcare entities operate under licenses, accreditations, and certifications that may be tied to the seller. State licenses, accreditation status, and government program certifications often have to be obtained or transferred for the new entity, and these run on regulatory timelines the buyer cannot compress. The exit cannot complete until the Newco can operate under its own authority.
The buyer inventories every license, accreditation, and program certification the operation depends on before the TSA clock matters. Each one needs a transition path, and some require surveys or inspections that have to be scheduled with regulators. A facility that loses its accreditation status during a transition can lose the ability to participate in government programs, which is a revenue event, not a paperwork delay.
Pharmacy and controlled substance registrations deserve specific attention where they apply. These carry their own registration requirements with strict chain of custody and reporting rules. The Newco has to hold its own registrations before it can handle controlled substances, and the transfer is a regulated process, not a name change on a form.
The buyer-side move is to treat licensure as a critical path workstream that runs parallel to the operational exit. Each authorization the operation needs is checked against the Newco's ability to obtain or transfer it in time. The diligence that supports this sits alongside the broader TSA exit strategy the buyer runs across the deal.
The healthcare exit sequence inverts the commercial playbook. Commercial carve-outs lead with systems and treat compliance as a workstream. Healthcare carve-outs lead with continuity of care, payer enrollment, and regulatory authority, and treat systems as the thing that has to fit inside those constraints. The buyer who sequences the other way around will strand revenue and risk care.
Practically, the critical path runs through payer enrollment and credentialing, then license and accreditation transfer, then clinical system cutover timed around care delivery. Back office separation, the bulk of an ordinary carve-out, is often the easiest part here because it sits away from patients and payers.
The governance has to include clinical and compliance leadership, not just IT and finance. Decisions about cutover timing on a clinical system are not purely commercial. They involve clinicians, compliance officers, and sometimes regulators. A governance structure that excludes them will commit to dates the operation cannot keep. The exit plan is socialized with clinical and compliance leaders early.
Healthcare carve-outs reward buyers who respect the constraints and punish those who treat them as friction. The enrollments take what they take. The compliance programs have to be real. Care cannot be disrupted. A buyer who plans the exit around those truths lands it. A buyer who plans around an idealized systems timeline pays the difference in stranded revenue, extension fees, and regulatory risk.
Patient data and continuity of care set the constraints. Protected health information, HIPAA obligations, clinical systems, and payer enrollment all gate the exit. A cutover that interrupts a clinical system or breaks a claims feed is a patient safety and revenue problem, not just an IT inconvenience.
The Newco must be enrolled and credentialed with payers under its own identifiers before it can bill for care delivered after the transition. Enrollment and credentialing run on payer and government timelines measured in months, and a gap means delivered care that cannot be billed. It is a gating workstream, not a back office task.
Protected health information cannot move to a system or party without the right agreements and safeguards. A routine migration becomes a regulated transfer governed by business associate agreements, access controls, and breach exposure. Seller side access to systems holding patient data has to be audited and closed at exit.
Clinical systems cannot go dark. Electronic health records, scheduling, and pharmacy systems support live patient care, so cutover is timed and validated to ensure no clinician loses access to the record they need. Continuity of care is the constraint the entire exit is designed around.
Where regulated quality systems and pharmacovigilance govern a life sciences exit.
Read the article →Where the quality system and regulatory registrations govern a device carve-out exit.
Read the article →Where regulatory approval and data controls govern a financial carve-out exit.
Read the article →The 90-day governance, IT, finance, HR and procurement separation plan we run on live carve-outs. Get the playbook plus the bi-weekly Day One Letter — short, signal-heavy, buyer-side.
No spam. Unsubscribe in one click. · Read the overview first →
Fixed-fee scope to sequence the exit around payer enrollment, HIPAA, and continuity of care. Senior team on day one. The first conversation is always free.
Seven buyer-side moves to exit a Transition Services Agreement on time and below budget. The mark-up, the extension-fee curve, exit sequencing, and the 11-month calendar.
A representative $90M-revenue life-sciences carve-out runs a Transition Services Agreement across eight functions, every one of them touching a validated system or regulated data. The moves below cut the exit from a 20-month drift to a 12-month managed exit and remove $2.5M of mark-up and stranded cost — while preserving the validated state and data integrity the regulators require.
One tactic, one benchmark, or one pattern from a recent buyer-side engagement. Short. Signal heavy. Free.
Subscribe to The Day One Letter →